Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

(HealthDay News) — Self-perceived stress is associated with cryptogenic ischemic stroke (CIS), according to a study published online March 5 in Neurology.

Self-perceived stress among young women was significantly associated with increased risk for early-onset cryptogenic ischemic ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to the manufacturer. Genentech said in a press release that TNKase ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Ischemic stroke is a fatal condition caused by an arterial embolism that blocks the blood flow through the cerebral artery, frequently being a cause of mortality and disability. Fibroblast growth ...

Blood types refer to a classification of blood based on substances present on your red blood cells. The four basic blood ...

The AcT (Alteplase compared to Tenecteplase) trial compared TNKase to Activase in treating patients with acute ischemic stroke that presented with a disabling neurological deficit. This ...

The US Food and Drug Administration has approved the thrombolytic tenecteplase for the treatment of patients with acute ischemic stroke, manufacturer Genentech announced today. The approval is based ...